Several expected factors associated with risk for endometrial cancer were reconfirmed in this study, including BMI, history of dyslipidemia, and PCOS; however, diabetes and hypertension were not confirmed.25,26 GnRH agonist treatment is associated with a higher risk of endometrial hyperplasia, although it has been shown that this treatment and the subsequently induced hypoestrogenism reduce the risk of endometrial diseases.27 This could be a consequence of the higher incidence of GnRH agonist use in the tamoxifen group. This evidence concerns the gene GNRH1 and metabolic syndrome.